News & Updates
Filter by Specialty:
Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers
Treatment with secukinumab leads to sustained clinical response among patients with psoriasis, with clinical response being associated with rapid and persistent normalization of keratin 16 (K16) and inflammatory gene expression for most patients, according to data from the ObePso-S study.
Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers
01 Apr 2023Long COVID: What are the risk and protective factors?
A population-based, multicentre study finds female gender, transportation-, logistics- or discipline-related occupation, living with domestic workers, smoking, poor or very poor self-perceived health status, ≥3 chronic diseases, chronic medication use, and critical severity of COVID-19 to be associated with severe long COVID, while prior receipt of ≥2 doses of COVID-19 vaccines serves as a protective factor.
Long COVID: What are the risk and protective factors?
01 Apr 2023Systemic antihypertensive medications exert diverse effects on glaucoma, IOP
The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.
Systemic antihypertensive medications exert diverse effects on glaucoma, IOP
31 Mar 2023Certain ART combinations carry some risk of depression among women with HIV
Women with HIV who use antiretroviral therapy (ART) combinations such as tenofovir alafenamide (TAF) with a cobicistat-boosted integrase inhibitor (INSTI) or protease inhibitor (PI) appear to frequently show somatic depressive symptoms, according to data from the Women’s Interagency HIV Study (WIHS) presented at CROI 2023.
Certain ART combinations carry some risk of depression among women with HIV
31 Mar 2023Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection
A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.
Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection
31 Mar 2023Novel device delivers improvements for BPH symptoms
The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.